There are disclosed a method for the treatment or prevention of immunoinflammatory conditions by administering to a mammal an effective amount of a compound having the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are each, independently, hydrogen, alkyl, aralkyl, aryl, or ##STR2## X is alkyl, aryl, or -NR.sup.5 R.sup.6 ; R.sup.5 and R.sup.6 are each independently hydrogen, alkyl, or aryl; aryl is ##STR3## where the dotted line represents an optional double bond; R.sup.7, and R.sup.8 and R.sup.9 are each, independently, hydrogen, alkyl, hydroxy, alkoxy, carbalkoxy, halo, nitro, amino, cyano, trifluoromethyl, or a carboxylic acid; n=1-3; or a pharmaceutically acceptable salt thereof.
A method of treating a patient suffering from allergic diseases, comprises administering to said patient an effective amount of a pharmaceutical composition in dosage unit form comprising a dry powder of guava leaves.
The present invention relates to the use of ellagic acid for the treatment of gastrointestinal disorders by stimulating the motility of the GI tract. In particular the present invention relates to a method of treatment of constipation, heartburn, non ulcer dyspepsia, GERD, and/or esophagitis, with a pharmaceutical composition comprising a safe and effective amount of ellagic acid or pharmaceutically acceptable salts or esters thereof. Preferably the ellagic acid is administered perorally.
